Benjamin H. Lowentritt, MD, FACS, Details Rationale for an Analysis Assessing How Clinical Factors Influence 18F-rhPSMA-7.3 Detection in Suspected Recurrent Prostate Cancer

CancerNetwork^® spoke with Benjamin H. Lowenritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, about the design of the phase 3 SPOTLIGHT study (NCT04186845) presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.Lowenritt indicated that the purpose was to determine the detection rate of 18F-rhPSMA-7.3 overall and in subgroups of patients with suspected recurrent prostate cancer.

Transcript:

The SPOTLIGHT trial is a study looking at 18F-rhPSMA-7.3, which is a novel PET PSMA agent used to help diagnose patients with prostate cancer. Specifically, the SPOTLIGHT study is looking at those patients who have biochemical recurrence after initial treatments for curative intent—either surgery or radiation—and the data is starting to emerge now that shows that it has good sensitivity and specificity. Specifically, this trial was looking at the overall detection rate, and then specifically the detection rates in certain subgroups.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.